E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 400.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,492 shares of the medical device company’s stock after purchasing an additional 62,000 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in DexCom were worth $5,214,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in DexCom by 1.8% during the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after purchasing an additional 866,506 shares during the last quarter. Jennison Associates LLC raised its position in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the period. Geode Capital Management LLC raised its position in shares of DexCom by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock worth $936,100,000 after buying an additional 358,617 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after acquiring an additional 1,868,241 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, COO Jacob Steven Leach acquired 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The shares were purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This represents a 5.81% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 7,866 shares of company stock worth $448,177. Insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.2%

Shares of NASDAQ DXCM opened at $67.57 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The stock’s 50-day simple moving average is $64.07 and its 200-day simple moving average is $73.11. The firm has a market cap of $26.35 billion, a price-to-earnings ratio of 37.54, a PEG ratio of 1.45 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm earned $0.45 EPS. DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DXCM shares. Mizuho lifted their price objective on DexCom from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Stifel Nicolaus initiated coverage on shares of DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price for the company. Robert W. Baird set a $82.00 price target on shares of DexCom in a research report on Friday, October 31st. Piper Sandler set a $75.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, BTIG Research dropped their price objective on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.